P360: Inflammatory microheterogeneity in ulcerative colitis: implications for microscopic assessment of disease activity
ECCO '19 Copenhagen
2019
P361: Laboratory criteria of infliximab therapy inefficiency in children with IBD
ECCO '19 Copenhagen
2019
P362: Faecal calprotectin is an early predictor of endoscopic response and histological remission after the start of vedolizumab
ECCO '19 Copenhagen
2019
P363: The minimal invasive surgery in combination with negative pressure wound therapy for perianal fistulas in Crohn’s colitis lead to the fast introduction of the biological treatment and improve the results
ECCO '19 Copenhagen
2019
P364: The value of faecal calprotectin for assessing endoscopic activity and predicting future clinical course in patients with active ulcerative colitis treated with granulomonocytapheresis: a prospective study
ECCO '19 Copenhagen
2019
P365: Autologous haematopoietic stem cell transplantation in refractory Crohn’s disease: experience of a Brazilian tertiary centre
ECCO '19 Copenhagen
2019
P366: A service evaluation of pre-operative nutritional optimisation in patients with Crohn’s disease using exclusive enteral nutrition with or without supplementary parenteral nutrition
ECCO '19 Copenhagen
2019
P367: Nutrition advice for IBD patients as a useful complementary strategy: a single-centre cohort intervention
ECCO '19 Copenhagen
2019
P368: Vedolizumab in inflammatory bowel disease: a retrospective single-centre study
ECCO '19 Copenhagen
2019
P369: The comparative frequency of clostridial infection in patients with ulcerative colitis receiving mesenchymal stromal cells and anti-cytokine therapy
ECCO '19 Copenhagen
2019
P370: Quality of life of patients with inflammatory bowel diseases in remission on different forms of treatment
ECCO '19 Copenhagen
2019
P371: Outcome of immediate infliximab optimisation based on rapid assessment of serum drug and faecal calprotectin concentrations in Crohn’s disease
ECCO '19 Copenhagen
2019
P372: Neurological symptoms and imaging abnormalities in brain MRI in patients with Crohn’s disease receiving anti-TNFa therapy
ECCO '19 Copenhagen
2019
P373: Effect of risankizumab on improved and sustained quality of life in patients with moderate to severe Crohn’s disease: Phase 2 trial results
ECCO '19 Copenhagen
2019
P374: Effects of subcutaneous vedolizumab on health-related quality of life and work productivity in patients with ulcerative colitis: results from the Phase 3 VISIBLE 1 trial
ECCO '19 Copenhagen
2019
P375: Inflammatory cutaneous lesions in inflammatory bowel disease treated with vedolizumab or ustekinumab: an ECCO CONFER multi-centre case series
ECCO '19 Copenhagen
2019
P376: Effects of IV vedolizumab on health-related quality of life and work productivity in patients with Crohn’s disease: results from the Phase 3b VERSIFY trial
ECCO '19 Copenhagen
2019
P377: Clinical strategies based on patient-reported outcomes and physicians’ preferences to monitor biological therapy in inflammatory bowel disease
ECCO '19 Copenhagen
2019